February 19th 2024
Amid shifting healthcare cost strategies, how manufacturers can apply past lessons to best support patients and help boost drug adherence.
February 7th 2024
As the market for biosimilars expands, a nuanced approach is needed to balance cost considerations with patient safety and pharmacovigilance efforts.
February 5th 2024
Higher prices of insulin attributed to significant annual increases, outpacing general inflation.
February 1st 2024
A look at how legislation—and the wider quest for more transparency on drug costs and reimbursement—may impact manufacturer product launch and pricing strategies in the years ahead.
November 14th 2023
Proposed legislation aims to address pharmacy benefit manager tactics to reduce prescription drug prices.
Drug Price Controls: “Red Meat for the Left” or Russian Roulette?
Kaiser’s August healthcare poll results should put all on high alert given public sentiment and the rhetoric of the political season. Ed Schoonveld sounds the alarm and offers four initiatives to stall the surge towards government intercession on escalating prices.
Express Scripts 2020: Back to the Future?
The clocks are ticking for Express Scripts, writes Stephen E. Littlejohn. Having achieved formidable “size and scale,” how will the nation’s largest pharmacy benefit manager synchronize with value-based health care?
The Bogus in Big Data
BIG DATA IS BIG-it’s the one trend in healthcare that demands to be described in superlatives.
The Dawn of the Age of Value Pricing in Cancer?
What will the ASCO Value Framework mean for the industry? Ram Subramanian from Simon-Kucher & Partners gives six items to think about.
The New Health: Navigating with Nash
Learnings gleaned from our annual EAB meeting, hosted this year by Dr. David Nash, Dean of the Thomas Jefferson University School of Population Health.
Pharma Pricing: Striking a Post-ACA Balance
Making sense of the new cost-containment model and value-for-money conundrums like those in the HCV space.
Can Payers and Drug Industry Agree on Real Value?
Recent developments in the pharmaceutical industry give the strong impression that both payers and industry are struggling to understand what represents “value” to customers, writes Ed Schoonveld.
Brand Strategies and the Growing Influence of IDNs
Pharm Exec speaks with IMS Health's John Daly and John Moran about new ways IDNs are impacting the healthcare decision landscape and the advantages of what they call “smart targeting”.
Partnering in a Volume to Value Transformational Environment
In the shift from volume to value as the underlying driver in health care, pharma has only scratched the surface of possibility for new and non-traditional arrangements with a broader variety of partners with healthcare interests, writes Cliff Kalb.
Are Global Markets Free-riding on the United States?
"Global free-riding" is the perception that the U.S. is subsidizing drugs for the rest of the world due to its high drug prices compared to other countries in the world.
Medicare Part B Data: Approach with Care
CMS's Part B data release has increased transparency but has also resulted in potentially misplaced scrutiny of high-billing doctors. Ben Scher, Kathleen Twigg, and Andrew Huson take a closer look.
The Best Price for the Most Revenue
A global life-cycle management strategy should be baked into a drug's initial price at launch, write Alice Swearingen and Patrick Homer.
Get Real: Preparing for the Real World Evidence Future
Why Real World Evidence (RWE) is here to stay, and what you need to do to integrate it into your business strategy as painlessly as possible.
Data has become as important as the drug in driving success in healthcare.
Betting on Bigger Data
In the rush to collect as much patient data as possible, are we sacrificing quality for quantity? Ben Comer reports.
AstraZeneca's Real-World Bet
In establishing the value of new medicines, old-way theory is yielding to real-world practice - but there are risks in being 'of the moment'.
Bridging the Hidden Hurdle in Cancer Cures
Diagnostics can bost the efficacy of drug treatments, but delivering the promise depends on a predictible pathway to reimbursement.
Co-Pay Cards: Pharma vs. Managed Care
Do drug co-pay cards lead to skyrocketing healthcare inflation or provide patients access to valuable medicines?
A New Twist in the Cost Curve
The strict regulatory divide between market authorization and price reimbursement iscrumbling in the US. Is industry prepared to adapt or challenge?
Roundtable: Deficit Reduction Act
The Deficit Reduction Act was designed to save the government money on Medicaid. But it also has the potential to change the very way pharma companies conduct business-if they can just figure it out.
2 Commerce Drive Cranbury, NJ 08512